Drugs that must not be present in the donors's blood

Introduction: Transfusion is probably the most humane area of drug use, as donors freely give a substance that serves as medicine, and even one person can save many lives, especially of newborns. The aim of this work is to single out drugs whose use prevents a voluntary donor from donating blood within a certain period of time. If we talk about blood quality, we must take into account that the presence of metabolites or active substances of certain drugs is a potential cause of adverse reactions in the recipient. Bearing in mind the practical importance of this problem, the authors of this paper make their contribution in order to make transfusion safer. Topic: The significance of this topic lies in plasma-containing components, where donor-used drugs may be present. The division of drugs potentially harmful to the health of the transfusion recipient is related to the pharmacokinetics, side effects, and drug interactions. Whole blood is less frequently transfused. In clinical practice, components are applied, such as erythrocytes resuspended in OAS (SAGMANITOL). The drug is present in the whole blood, and by separating the cellular components, it becomes present in the plasma. The concentration of the drug in the stored blood component depends on the pharmacokinetic characteristics (t/2) of the drug, retention of the drug or metabolites in the donor's circulation. In fact, attention should be focused on the components that contain plasma: plasma, cryoprecipitate and platelet concentrates (PC). Overall, drug use should be divided into groups that temporarily exclude donors and groups that permanently exclude donors. Genetic vaccines are a new form of medicine that alarmingly points to the monitoring of distant side effects due to the presence of spike proteins. Conclusion: Drugs in transfusion as professional topic must be covered by local guides and SOPs of blood establishments and hospital blood banks. A regulation should be established defining drugs that are contraindications for donating. Modern analytical methods should be used as needed to detect the presence of drugs and their metabolites. Apart from the caution related to the presence of the drug in the blood/components, the biggest harm to the patient can be caused by the ambitious use of mRNA technology drugs and insufficient knowledge about this group of drugs. In medically unclear situations, the authors agree with the position of patient blood management that autotransfusion is the solution. The obligation for pharmacovigilance and hemovigilance should be legally regulated.